Genelux Corp. (GNLX) Live Share Price, Invest From India

Genelux Corp. Stock Performance

as on August 24, 2026 at 2:16 pm IST

Day's Low
Day's High
$2.69
Day's Price Range
$2.81
$2.72
1.10%
Downside
3.31%
Upside
52 Week's Low
52 Week's High
$2.29
52-Week Price Range
$8.54
$2.72
15.81%
Downside
213.79%
Upside

Genelux Corp. share price movements today

Previous Close: $2.74
Open: $2.78
Volume: 451.2K
Market Cap: $122.9M
Day's Low - High: $2.69 - $2.81
52 Week Low - High: $2.29 - $8.54

Genelux Corp. Historical Returns

1 Month Return: -4.53 %
3 Month Return: -6.16 %
1 Year Return: -23.03 %
3 Year Return: -88.33 %
5 Year Return: 0 %

Genelux Corp. Stock Fundamentals & Key Indicators

Check Genelux Corp. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$122.9M

EPS (TTM)

-0.88

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.96

Industry PE ratio

-1.5966015625

PEG Ratio

1.2449165327068197

EBITDA

-32.0M

Revenue (TTM)

8.0K

Profit Margin

-1762.50%

Return On Equity TTM

-195.42%

Genelux Corp. Stock Valuation

Track how Genelux Corp. P/E has moved over time to understand its valuation trends.

Genelux Corp. in the last 5 years

Overview
Trends

Lowest (-29.00x)

December 31, 2022

Today (-5.07x)

December 31, 2025

Industry (-1.60x)

December 31, 2025

Highest (-2.48x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -5.07x

Genelux Corp. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Genelux Corp. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Genelux Corp.	BUY	$122.9M	NA	-2.96	-1762.50%	NA
Revolution Medicines	BUY	$43.7B	669.3%	NA	0.00%	NA
Vertex Pharmaceuticals	BUY	$128.2B	154.86%	29.82	86.04%	NA
Moderna	BUY	$25.3B	-84.24%	-7.98	-12.57%	NA
Regeneron	BUY	$82.7B	24.1%	19.24	84.86%	0.44999999999999996%

Stock Returns calculator for Genelux Corp. Stock including INR - Dollar returns

The Genelux Corp. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Genelux Corp. investment value today

Current value as on today

₹83,470

Returns

-₹16,530

(-16.53%)

Returns from Genelux Corp. Stock

-₹23,596 (-23.6%)

Dollar Impact

₹7,065 (+7.07%)

Analyst Recommendation on Genelux Corp. Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Genelux Corp.. Average target price of $17.5

Genelux Corp. Share Price Target

Get share price movements and forecasts by analysts on Genelux Corp..

What analysts predicted

84.46%UPSIDE

Target Price

$17.5

Current Price

$2.72

Analyzed by

1 Analysts

Target

$17.50

Genelux Corp. target price $17.5, a slight upside of 84.46% compared to current price of $2.72. According to 1 analysts rating.

Indian Investors' Interest in Genelux Corp. Stock

Search interest for Genelux Corp. Stock has increased by 64% in the last 30 days, reflecting an upward trend in search activity.

Time period: July 25, 2026 to August 24, 2026

Change:64% versus previous 30 day period

Genelux Corp. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	0	-	-	-	-	-	-	0	-
Gross Profit	0	0	0	-	-	-	0	-	0	0
Operating Income	-5	-8	-6	-6	-9	-7	-7	-8	-9	-8
EBITDA	-5	-7	-6	-6	-8	-7	-7	-7	-9	-7
Interest Expense	0	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-5	-7	-6	-6	-8	-7	-7	-7	-9	-7
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-5	-7	-6	-6	-8	-7	-7	-7	-9	-7
Net Profit Margin	0.00%	-3000.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1750.00%	0.00%

Genelux Corp. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Mar 2024	Dec 2024	Dec 2025
Total Revenue	-	-	-	11	0	0	0
Gross Profit	-	0	0	10	0	0	0
Operating Income	-10	-12	-14	-3	-24	-31	-33
EBITDA	-10	-11	-13	-1	-26	-28	-31
Interest Expense	0	1	1	1	3	-	-
Depreciation	0	0	0	0	1	0	0
Income Before Tax	-11	-13	-16	-4	-28	-29	-32
Income Tax Expense	-	-	-	1	-	-	-
Net Income	-11	-14	-17	-5	-28	-29	-32
Net Profit Margin	0.00%	0.00%	0.00%	91.25%	-498.82%	-11187.50%	-7075.00%

Genelux Corp. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-5	-7	-6	-6	-8	-7	-7	-7	-9	-8
Operating Cash Flow	-3	-4	-6	-5	-4	-5	-7	-6	-6	-6
Investing Cash Flow	0	-1	-17	3	6	3	-2	4	6	-8
Financing Cash Flow	6	0	27	-	0	9	0	-	0	18
Change in Cash	2	-5	3	-1	2	7	-9	-1	0	3

Genelux Corp. Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Mar 2024	Dec 2024	Dec 2025
Net Income	-11	-13	-16	-5	-28	-29	-32
Operating Cash Flow	-7	-7	-6	-3	-20	-21	-25
Investing Cash Flow	-1	0	-	0	-14	-8	12
Financing Cash Flow	7	18	0	0	44	28	9
Change in Cash	-1	10	-6	-4	9	0	-3

Mutual Funds that own Genelux Corp. Stock

Check out the Mutual Funds with significant holdings in Genelux Corp..

Funds	Holdings	Shares Held
VANGUARD INDEX FUNDS	3.702289%	1660122
Fidelity Concord Street Trust	0.698479%	313201
TIAA-CREF Funds	0.056252%	25224
SCHWAB CAPITAL TRUST	0.055753%	25000
GOLDMAN SACHS TRUST	0.054896%	24616

See all

Global Institutional Holdings in Genelux Corp.

Funds	Holdings
Vanguard	3.7%
iShares	0.31%

Insights on Genelux Corp.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 558.3% return, outperforming this stock by 646.9%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 494.0%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 896.0K → 8.0K (in $), with an average decrease of 73.9% per quarter
NEGATIVE IMPACT
Price Dip
In the last 3 years, GNLX stock has moved down by -88.6%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -7.12M → -9.47M (in $), with an average decrease of 32.9% per quarter

About Genelux Corp.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Organisation	Genelux Corp.
Headquarters	2625 Townsgate Road, Westlake Village, CA, United States, 91361
Industry	Biotechnology
CEO	Mr. Thomas D. Zindrick J.D.
E-voting on shares	Click here to vote

Key Management of Genelux Corp.

Name	Title
Mr. Thomas D. Zindrick J.D.	Chairman, CEO & President
Mr. Matthew Pulisic M.B.A.	CFO and Principal Financial & Accounting Officer
Dr. Joseph Cappello Ph.D.	Chief Technical Officer
Dr. Yong Yu Ph.D.	Chief Scientific Officer
Mr. Eric Groen J.D.	General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
Mr. Ralph Smalling B.Sc.	VP & Head of Regulatory Affairs
Dr. Jason B. Litten M.D.	Chief Medical Officer

FAQs

What is Genelux Corp. share price today?

Genelux Corp. share price today is $2.72 as on August 24, 2026 at 8:46 am IST at the close of the market. Genelux Corp. share today touched a day high of $2.81 and a low of $2.69.

What is the 52 week high and 52 week low for Genelux Corp. share?

Genelux Corp. share touched a 52 week high of $8.54 on November 5, 2025 and a 52 week low of $2.29 on March 30, 2026. Genelux Corp. stock price today i.e. August 24, 2026 at 8:46 am IST is closed at $2.72,which is 68.13% down from its 52 week high and 18.78% up from its 52 week low.

What is Genelux Corp.'s market capitalisation today?

Genelux Corp. market capitalisation is $0.00T as on August 24, 2026 at 8:46 am IST.

How to invest in Genelux Corp. Stock (GNLX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Genelux Corp. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Genelux Corp. Shares that will get you 0.5515 shares as per Genelux Corp. share price of $2.72 per share as on August 24, 2026 at 8:46 am IST.

What is the minimum amount required to buy Genelux Corp. Stock (GNLX) from India?

Indian investors can start investing in Genelux Corp. (GNLX) shares with as little as ₹95.71 or $1 (as of August 24, 2026 at 4:41 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in Genelux Corp. stock (as per the Rupee-Dollar exchange rate as on August 24, 2026 at 4:41 pm IST). Based on Genelux Corp. share’s latest price of $2.72 as on August 24, 2026 at 8:46 am IST, you will get 3.6765 shares of Genelux Corp.. Learn more about fractional shares .